Last reviewed 2026-05-28 · How we verify

Thoracic interfascial plane block

Tanta University · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

Thoracic interfascial plane block is a Small molecule drug developed by Tanta University. It is currently in Phase 1 development.

The thoracic interfascial plane block is a type of regional anesthesia used to manage postoperative pain, particularly after thoracotomy. It has been compared to thoracic epidural analgesia in clinical trials, such as the study "Continuous Erector Spinae Plane Block Versus Thoracic Epidural Analgesia After Thoracotomy," to evaluate its analgesic efficacy.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Thoracic interfascial plane block
Sponsor	Tanta University
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Thoracic interfascial plane block CI brief — competitive landscape report
Thoracic interfascial plane block updates RSS · CI watch RSS
Tanta University portfolio CI

Frequently asked questions about Thoracic interfascial plane block

What is Thoracic interfascial plane block?

Thoracic interfascial plane block is a Small molecule drug developed by Tanta University.

Who makes Thoracic interfascial plane block?

Thoracic interfascial plane block is developed by Tanta University (see full Tanta University pipeline at /company/tanta-university).

What development phase is Thoracic interfascial plane block in?

Thoracic interfascial plane block is in Phase 1.

Manufacturer: Tanta University — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing